Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Obe-Cel Is Associated With Improved Outcomes in R/R B-ALL With Low-Risk CAR-HT Scores
February 13th 2025, 5:10pm
Transplantation and Cellular Therapy Meetings
A high-risk CAR-HEMATOTOX score was associated with worse outcomes with obe-cel in relapsed/refractory B-ALL.
Oncology Experts Preview Top Abstracts From 2025 ASCO GU
February 12th 2025, 11:06pm
Genitourinary Cancers Symposium (ASCO GU)
Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium.
Dr Somaiah on Ongoing Research With Novel Agents in Sarcomas
February 12th 2025, 9:18pm
Miami Cancer Institute Precision Oncology Symposium
Neeta Somaiah, MD, discusses ongoing research with novel agents that have emerged and those that could soon emerge in the sarcoma treatment paradigm.
Dr Hamid on the Potential for Cancer Vaccines in Melanoma
February 12th 2025, 12:42am
PER® International Symposium on Melanoma and Other Cutaneous Malignancies
Omid Hamid, MD, provides insight on the potential role of cancer vaccines in melanoma.
Dr Orloff on Treatment Strategies for Rapidly Progressing Uveal Melanoma
February 11th 2025, 11:04pm
PER® International Symposium on Melanoma and Other Cutaneous Malignancies
Marlana M. Orloff, MD, discusses optimal therapeutic approaches for patients with uveal melanoma that is rapidly progressing.
Dr Faries on Emerging CAR T-Cell and TCR Cell Therapies in Melanoma
February 11th 2025, 10:59pm
PER® International Symposium on Melanoma and Other Cutaneous Malignancies
Mark Faries, MD, discusses how CAR T-cell and TCR cell therapies compare with TIL approaches in melanoma.
Targeted Therapies for NSCLC With Nonclassical EGFR Mutations Grow Increasingly Personalized
February 4th 2025, 7:00pm
PER® Winter Lung Cancer Conference
The variety of nonclassical EGFR mutations in NSCLC necessitates the development of unique treatment strategies based on individual mutational profiles.
Next-Generation Sequencing Data Inform IO Treatment Sequencing in NSCLC
February 3rd 2025, 9:59pm
PER® Winter Lung Cancer Conference
KEAP1 and STK11 have emerged as potential biomarkers of response to immuno-oncology combinations in frontline NSCLC.
Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
February 3rd 2025, 2:00pm
Gastrointestinal Cancers Symposium (ASCO GI)
The combination of botensilimab plus balstilimab elicited high major pathologic response rates with extended time to surgery in resectable colorectal cancer.
Comparable Survival Outcomes Observed With Atezolizumab/Bevacizumab vs Tremelimumab/Durvalumab in First-Line HCC
February 3rd 2025, 1:00pm
Gastrointestinal Cancers Symposium (ASCO GI)
Clinical outcomes did not significantly differ with atezolizumab plus bevacizumab vs tremelimumab and durvalumab in treatment-naive, unresectable HCC.
Dr Mekhail on a Case Study of Early-Stage, Nonmetastatic Lung Cancer
February 2nd 2025, 7:15pm
PER® Winter Lung Cancer Conference
Tarek Mekhail, MD, MSc, FRCSI, FRCSEd, discusses a case study of a patient with early-stage, nonmetastatic lung adenocarcinoma.
Dr Levy on the Development and Clinical Use of ADCs in NSCLC
February 2nd 2025, 7:05pm
PER® Winter Lung Cancer Conference
Benjamin P. Levy, MD, discusses the current clinical and developmental statuses of several ADCs for patients with non–small cell lung cancer.
Shields Spotlights Lessons Learned in Limited-Stage SCLC and Areas Ripe for Further Research
February 2nd 2025, 1:00pm
PER® Winter Lung Cancer Conference
Misty Shields, MD, PhD, provides a comprehensive overview of key updates in. the management of limited-stage small cell lung cancer.
Dr Hales on the Use of Post-Operative Radiotherapy in NSCLC
February 2nd 2025, 1:45am
PER® Winter Lung Cancer Conference
Russell Hales, MD, discusses clinical data that challenge the use of post-operative radiotherapy in patients with non–small cell lung cancer.
Dr Rodriguez on a Case Study of EGFR-Mutated NSCLC
February 2nd 2025, 1:20am
PER® Winter Lung Cancer Conference
Estelamari Rodriguez, MD, MPH, discusses a case study of a patient with non–small cell lung cancer harboring an EGFR L858R mutation and a TP53 mutation.
Expanded Targets, Synergistic Regimens Are Needed to Propel NSCLC Beyond Anti–PD-1 Therapy
February 2nd 2025, 12:18am
PER® Winter Lung Cancer Conference
Melissa L. Johnson, MD, discusses the evolution of immunotherapy approaches beyond PD-1 inhibition in lung cancer.
Data Help Refine Optimal Radiotherapy Approaches in Small Cell Lung Cancer
February 1st 2025, 9:04pm
PER® Winter Lung Cancer Conference
Walter J. Curran, MD, discusses the evolving use of radiotherapy in small cell cancer and data supporting its optimal use.
Dr Moore on the Relationship Between Biomarker Expression and Efficacy With ADCs in Ovarian Cancer
February 1st 2025, 8:53pm
Kathleen N. Moore, MD, MS, discusses the relationship between biomarker expression and efficacy with antibody-drug conjugates in ovarian cancer.
Dr Chase on the Importance of QOL and PRO Measures in Gynecologic Oncology
February 1st 2025, 8:53pm
Dana M. Chase, MD, discusses the importance of quality of life and patient-reported outcome measures in gynecologic oncology.
Dr Shields on Key ADRIATIC Trial Data With Adjuvant Durvalumab in LS-SCLC
February 1st 2025, 1:55am
PER® Winter Lung Cancer Conference
Misty D. Shields, MD, PhD, discusses the implications of the ADRIATIC trial of adjuvant therapy with durvalumab vs placebo in patients with LS-SCLC.